Facet Biotech

In 2017, while working in a drug pricing and commercialization consultancy, I prepared a slide analyzing the 2016 sales of the 35 novel drugs that were approved in 2011. I have just repeated the exerc

When bluebird bio announced its plans to split into two separately listed entities, analysts were enthusiastic and social media commentators compared it to a different, recently well-received transa

FDA took the next step to raise the regulatory standards for blood lancets in response to concerns about spreading infectious disease. The devices used to prick a patient's finger for a blood sample h

Stock prices for Ambit Biosciences and Emergent BioSolutions dipped after abstracts for their data presentations at the upcoming American Society of Hematologists (ASH) Annual Meeting and Exposition b